Φορτώνει......
GSK923295 as a potential antihepatocellular carcinoma agent causing delay on liver regeneration after partial hepatectomy
BACKGROUND: The clinical trials emerged centromere protein E inhibitor GSK923295 as a promising anticancer drug, but its function in hepatocellular carcinoma (HCC) remain needs to be fully elucidated, especially as chemotherapy after hepatectomy for liver tumors. We aimed to describe anti-HCC activi...
Αποθηκεύτηκε σε:
| Τόπος έκδοσης: | Chin Med J (Engl) |
|---|---|
| Κύριοι συγγραφείς: | , , , , , , |
| Μορφή: | Artigo |
| Γλώσσα: | Inglês |
| Έκδοση: |
Wolters Kluwer Health
2019
|
| Θέματα: | |
| Διαθέσιμο Online: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6595801/ https://ncbi.nlm.nih.gov/pubmed/30681497 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1097/CM9.0000000000000053 |
| Ετικέτες: |
Προσθήκη ετικέτας
Δεν υπάρχουν, Καταχωρήστε ετικέτα πρώτοι!
|